CRP and cardiovascular disorder: Additionally, clinical trials involving n-6 have yet to measure inflammatory markers that are downstream of the elevated PGE2 (such as IL-17 and the Th17 pathway) [43] or directly investigate the TLR4 axis, and instead focus on the more traditional Th1 markers of TNF, C-reactive protein (CRP), or cardiovascular disease [69].